Machine-learning selection of a six-protein panel for atherosclerosis severity and patient stratification
Five machine-learning classifiers integrated clinical and serum-proteomic data from carotid atherosclerotic stenosis (60 participants), dyslipidemia (55) and healthy controls (66). A consensus approach identified a six-protein panel (B2M, GPV, MMP9, PLF4, TSP1 and fibrinogen/FB isoforms) that distinguished the atherosclerosis group from the comparison groups, with reported ROC-AUC above 0.9 across the tested classifiers. Protein levels were evaluated by flow cytometry and ELISA in an independent external cohort that included patients with acute atherothrombotic stroke.
Technology: Five machine-learning classifiers: Naive Bayes, linear SVM, random forest, Extra Trees and AdaBoost
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: A consensus approach identified a six-protein panel (B2M, GPV, MMP9, PLF4, TSP1 and fibrinogen/FB isoforms) that distinguished the atherosclerosis group from the comparison groups, with reported ROC-AUC above 0.9 across the tested classifiers.
- Still unknown: The discovery cohorts were small (60 atherosclerosis, 55 dyslipidemia and 66 healthy controls); external validation supports the measured panel but does not establish population-wide performance, prospective clinical utility, or improved patient outcomes. The proteins have prior biological associations, so the finding is the specific integrated panel and cohort discrimination rather than discovery of six new proteins or a new mechanism.
- AI role: Five classifiers integrated clinical and serum-proteomic features and selected a consensus six-protein panel for patient-group discrimination. The authors then evaluated the selected proteins in an independent clinical cohort using flow cytometry and ELISA.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41961364/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.